Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

fludarabine 6Cyclophosphamide 5fludarabine phosphate 4Melphalan 3Busulfan 3trametinib 2thymoglobulin 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Cytarabine 2Biopsy 2omipalisib 1merphos 1imetelstat 1hydrocortisone hemisuccinate 1blinatumomab 1Transplantation 1Thiotepa 1Spinal Puncture 1Sirolimus 1Rituximab 1Radiotherapy 1Mesna 1Levetiracetam 1Leucovorin 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Juvenile × hydrocortisone hemisuccinate × 90 days × Clear all
NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡